The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells

被引:11
作者
Dar, Javid A. [1 ,4 ]
Masoodi, Khalid Z. [1 ]
Eisermann, Kurtis [1 ]
Isharwal, Sudhir [1 ]
Ai, Junkui [1 ]
Pascal, Laura E. [1 ]
Nelson, Joel B. [1 ,3 ]
Wang, Zhou [1 ,2 ,3 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15232 USA
[2] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15232 USA
[4] King Saud Univ, Coll Sci, Cent Lab, Riyadh Ksa 11451, Saudi Arabia
基金
美国国家卫生研究院;
关键词
AMINO-ACID SUBSTITUTIONS; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; TRANSACTIVATION DOMAIN; INSENSITIVITY SYNDROME; COMPLEMENTARY-DNA; HSP90; INHIBITOR; LIGAND; MUTATION; IDENTIFICATION;
D O I
10.1016/j.jsbmb.2014.03.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Androgen-independent nuclear localization is required for androgen receptor (AR) transactivation in castration-resistant prostate cancer (CRPC) and should be a key step leading to castration resistance. However, mechanism(s) leading to androgen-independent AR nuclear localization are poorly understood. Since the N-terminal domain (NTD) of AR plays a role in transactivation under androgen-depleted conditions, we investigated the role of the NTD in AR nuclear localization in CRPC. Deletion mutagenesis was used to identify amino acid sequences in the NTD essential for its androgen-independent nuclear localization in C4-2, a widely used CRPC cell line. Deletion mutants of AR tagged with green fluorescent protein (GFP) at the 5'-end were generated and their signal distribution was investigated in C4-2 cells by fluorescent microscopy. Our results showed that the region of a.a. 294-556 was required for androgen-independent AR nuclear localization whereas a.a. 1-293 mediates Hsp90 regulation of AR nuclear localization in CRPC cells. Although the region of a.a. 294-556 does not contain a nuclear import signal, it was able to enhance DHT-induced import of the ligand binding domain (LBD). Also, transactivation of the NTD could be uncoupled from its modulation of AR nuclear localization in C4-2 cells. These observations suggest an important role of the NTD in AR intracellular trafficking and androgen-independent AR nuclear localization in CRPC cells. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:473 / 480
页数:8
相关论文
共 50 条
[21]   The expression of AURKA is androgen regulated in castration-resistant prostate cancer [J].
Kivinummi, Kati ;
Urbanucci, Alfonso ;
Leinonen, Katri ;
Tammela, Teuvo L. J. ;
Annala, Matti ;
Isaacs, William B. ;
Bova, G. Steven ;
Nykter, Matti ;
Visakorpi, Tapio .
SCIENTIFIC REPORTS, 2017, 7
[22]   Characterization of Niphatenones that Inhibit Androgen Receptor N-Terminal Domain [J].
Banuelos, Carmen A. ;
Lal, Aaron ;
Tien, Amy H. ;
Shah, Neel ;
Yang, Yu Chi ;
Mawji, Nasrin R. ;
Meimetis, Labros G. ;
Park, Jacob ;
Kunzhong, Jian ;
Andersen, Raymond J. ;
Sadar, Marianne D. .
PLOS ONE, 2014, 9 (09)
[23]   Editorial Comment to Androgen receptor targeted therapies in castration-resistant prostate cancer: Bench to clinic [J].
Sakamoto, Shinichi .
INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (08) :666-666
[24]   Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer [J].
Ponnusamy, Suriyan ;
Coss, Christopher C. ;
Thiyagarajan, Thirumagal ;
Watts, Kate ;
Hwang, Dong-Jin ;
He, Yali ;
Selth, Luke A. ;
McEwan, Iain J. ;
Duke, Charles B. ;
Pagadala, Jayaprakash ;
Singh, Geetika ;
Wake, Robert W. ;
Ledbetter, Christopher ;
Tilley, Wayne D. ;
Moldoveanu, Tudor ;
Dalton, James T. ;
Miller, Duane D. ;
Narayanan, Ramesh .
CANCER RESEARCH, 2017, 77 (22) :6282-6298
[25]   Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions [J].
Leibowitz-Amit, R. ;
Joshua, A. M. .
CURRENT ONCOLOGY, 2012, 19 :S22-S31
[26]   A sting in the tail: the N-terminal domain of the androgen receptor as a drug target [J].
Monaghan, Amy E. ;
McEwan, Iain J. .
ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (05) :687-694
[27]   Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer [J].
Kregel, Steven ;
Chen, James L. ;
Tom, Westin ;
Krishnan, Venkatesh ;
Kach, Jacob ;
Brechka, Hannah ;
Fessenden, Tim B. ;
Isikbay, Masis ;
Paner, Gladell P. ;
Szmulewitz, Russell Z. ;
Vander Griend, Donald J. .
ONCOTARGET, 2016, 7 (18) :26259-26274
[28]   Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer [J].
Shankar, Eswar ;
Franco, Daniel ;
Iqbal, Omair ;
Moreton, Stephen ;
Kanwal, Rajnee ;
Gupta, Sanjay .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 404
[29]   Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer [J].
Kregel, Steven ;
Kiriluk, Kyle J. ;
Rosen, Alex M. ;
Cai, Yi ;
Reyes, Edwin E. ;
Otto, Kristen B. ;
Tom, Westin ;
Paner, Gladell P. ;
Szmulewitz, Russell Z. ;
Vander Griend, Donald J. .
PLOS ONE, 2013, 8 (01)
[30]   Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer [J].
Liu, Chengfei ;
Lou, Wei ;
Zhu, Yezi ;
Nadiminty, Nagalakshmi ;
Schwartz, Chad T. ;
Evans, Christopher P. ;
Gao, Allen C. .
CLINICAL CANCER RESEARCH, 2014, 20 (12) :3198-3210